Regulatory pathway

Determining the regulatory path for a combination product is a difficult task. Even in the USA, which seems to have given the most consideration for and focus on defining and regulating combination products, it still involves much uncertainty.

Anne Dupraz Poiseau, Executive Vice President 

Responsible for the definition of the Corporate Strategy and Business Development implementation plan. Participation in the structuration of the Company to allow future growth (internal and through acquisition). Managerial and expertise responsibilities and acts as senior Advisor on Advanced Therapies Medicinal Products (ATMPs, in particular on cell and tissue based therapies), combination products (drug/device combinations) and medical devices related projects (incl. e- and m-health). 

Download the full Publication now